Atlas Trials

Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer

Clinical trial NCT01150513 · COMPLETED

Trial details

NCT number
NCT01150513
Sponsor
Chinese Academy of Medical Sciences
Status
COMPLETED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Breast Cancer
Start date
2009-06-01
Primary completion
2016-01-01
Enrollment
320

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.